Plus Therapeutics (PSTV) Cash & Current Investments (2010 - 2026)

Plus Therapeutics (PSTV) has 17 years of Cash & Current Investments data on file, last reported at $15.1 million in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $15.1 million, up 53.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.1 million (up 53.18% YoY), and the FY2025 annual result was $8.6 million, up 138.82% from the prior year.
• Cash & Current Investments improved to $15.1 million in Q1 2026 per PSTV's latest filing, from $8.6 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $21.2 million in Q1 2022 and troughed at $397000.0 in Q1 2024.
• A 5-year average of $11.5 million and a median of $10.9 million in 2023 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2024 and 2025: Cash & Current Investments plunged 96.88% in 2024, then jumped 2385.39% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $18.1 million in 2022, then tumbled by 52.79% to $8.6 million in 2023, then slumped by 57.84% to $3.6 million in 2024, then surged by 138.82% to $8.6 million in 2025, then soared by 75.5% to $15.1 million in 2026.
• Business Quant data shows PSTV's Cash & Current Investments at $15.1 million in Q1 2026, $8.6 million in Q4 2025, and $16.6 million in Q3 2025.